RA Capital Management is a venture capital and private equity firm investing in public and private healthcare and life science companies that is headquartered in Boston, Massachusetts and was founded in 2004 by Richard Aldrich.
As of December 2019, RA Capital Management has made 114 investments, lead 28 investments, and made a total of 62 exits. Notable investments made by Ra Capital Management (as of December 2019) include: Audentes Therapeutics, 89bio, Bluebird Bio, Precision BioSciences, Moderna Therapeutics, Peloton Therapeutics, Orchard Therapeutics, Phathom Pharmaceuticals, Global Blood Therapeutics, and AveXis.
On July 15, 2019 RA Capital Management announced raising $308 million for their RA Capital Nexus Fund. The fund increases the firms deal capiacity to $1 billion, and the total managed assets to about $2.5 billion. The firms plans on using the fund to invest in companies working on products and services realted to neurology, oncology, cardiovascular disease, and rare diseases.
A biotechnology startup company that develops messenger RNA based therapeutics to treat diseases.
Precision BioSciences is a biotechnology developing a gene editing platform for the creation of cell therapies, gene therapies, and agricultural products.
Silicon Valley-based genetic engineering startup.
A biopharmaceutical company that develops treatments for multi-drug resistant (MDR) bacterial infection
Antera Therapeutics is an allergy prevention development company.
Seres Therapeutics is a microbiome therapeutics company that was founded in 2010 and headquartered in Cambridge, Massachusetts.
Clinical stage biotechnology company focused on treating infectious diseases using recombinant nanoparticle vaccine technology
ViaCyte is a biotechnology company using stem cells to create pancreatic beta cell precursors for treating diabetes.
Synthetic biology company that created novel DNA base pairs and uses them to incorporate novel amino acids into proteins for potential therapeutics in areas of cancer and autoimmune disorders.
T2 Biosystems is a Lexington, Massachusetts-based company developing diagnostic products targeting sepsis and in vitro diagnostic products intended to target sepsis, hemostasis, bacteria, and lyme disease founded in 2006 by Robin Toft.
Now known as Sierra Oncology, is a clinical stage drug development company in Vancouver that focuses on cancer and hematology treatments.
Nkarta Therapeutics is a biotechnology company using natural killer (NK) immune cells for cellular therapies.
A biotechnology company in California that focuses on developing, manufacturing and commercializing biologic therapeutics or biosimilars for oncology and inflammatory diseases.
A biopharmaceutical company developing chemoproteomics for drug discovery.
Solid Biosciences is a Cambridge, Massachusetts-based biotechnology company focused on solving Duchenne muscular dystrophy.
Vor BioPharma is a biotechnology company developing hematopoietic stem cell therapy treatments for cancer.
Dimension Therapeutics is a biotechnology company that uses gene therapy to treat liver diseases.
Immunotherapy company focused on autoimmune diseases and cancer
Stoke Therapeutics is a biopharma company that develops RNA-targeted treatments for severe genetic diseases.
A Forma Therapeutics is a bio-pharmaceutical company that focuses on therapeutics for rare hematological diseases and cancer.
Akouos is a Brookline, Massachusetts-based biotechnology company developing precision genetics-based medicines founded in 2016 by Emmanuel Simons.
Orchard Therapeutics is a biotechnology company developing gene therapies for rare diseases.
Seres Health is a Cambridge, Massachusetts-based company founded by David Berry.
Andrew Levin, MD, PhD
Ben Dake, PhD
Chieze Ibeneche-Nnewihe, PhD
Derek DiRocco, PhD
Jake Simson, PhD
Jamie Kasuboski, PhD
Venture Senior Associate
Josh Resnick, MD
Mary Pat Connolly
Investment Research Coordinator
Matthew Hammond, PhD
Nathanial Brooks Horowitz
Corporate Development Manager
Peter Kolchinsky, PhD
Ryan Berry, PhD
Zach Scheiner, PhD